Episode 45: AI doctors: how close are they? With Robert Sargsyan, CEO of Docus. Will AI doctors eventually replace human doctors? Are they already doing so? On one hand, people like the human touch of human doctors. On the other hand, human doctors get tired, are limited in terms of the amount of data they can handle and tend to be overstretched. So where are we with the development of AI doctors? Joining me is someone at the cutting edge of this fascinating topic, Robert Sargsyan, CEO of Docus.

Will AI doctors eventually replace human doctors? Are they already doing so? On one hand, people like the human touch of human doctors. On the other hand, medical AI systems could solve many problems in healthcare. So, where are we with the development of AI doctors? Joining me is someone at the cutting edge of this fascinating topic …Robert Sargsyan, CEO of Docus.

Irregular heart rhythms can indicate several potentially fatal health problems, including risk for heart attack and stroke. Here we discuss how AI approaches are helping to transform cardiology, with respect to detection of irregular heart rhythms. With Felix is Stuart Long, CEO of infobionic.ai

Waiting for emergency treatment, when you might already be in shock, can be a very distressing and lonely experience. A big part of the problem might be that you are feeling in the dark about what’s happening and how long you’ll be there. An already stressful situation could feel like an eternity. How can AI systems help here? Two men who have commercialised just such a thing are Aaron Patzer and Dr Justin Schrager, founders of the company Vital.

Some have suggested that the medical profession is a force of resistance in AI adoption, that it is prioritizing the protection of jobs, potentially at the cost of patients

Is there any truth in that?

Or is the medical profession actually protecting

With me is someone who is perfectly placed to discuss this, Dr Jethro Hubbard. He is a GP. And he was also instrumental in the introduction of the BMA policy on healthcare AI integration.

AI has the potential to revolutionize clinical trials in many ways. It could make the development of new treatments faster, safer, cheaper and more personalised. One company in this space is Owkin, a unicorn startup based in Paris. With me is Dr Félix Balazard, Director of

Clinical trials are the cornerstone of the development of new treatments. One can see them as a shining example of the scientific method in practice. One can also see them as phenomenally expensive, with a high rejection

With me to discuss this is Dr Harsha Rajasimha, CEO of Jeeva Clinical Trials.

Counterfeit medications and medical equipment is a huge global fraud. And it is deadly - counterfeit medications can contain incorrect ingredients and even harmful components. So how far is it possible to detect

The Medical AI Podcast is one of Feedspot's top rated podcasts: https://blog.feedspot.com/uk_ai_podcasts/

Imagine having crippling back pain, but there’s a four month waiting list for a physiotherpist. Alternatively, you have instant access to an AI-based physiotherapy system. 80% of adults have significant back pain at some point, so there’s an excellent chance that this kind of choice is one you will have to make.

But can it be made to work? Is the technology ready? Would it be accepted by governments and patients? Are there issues with patient safety?

With me is Finn Stevenson, who is working on precisely this idea. He is a former medic, and CEO of Flok Health.

Episode 41: The path to a medical AI holy grail: medical records analysis and automated treatment selection; with Mika Newton, CEO of XCures